<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207801</url>
  </required_header>
  <id_info>
    <org_study_id>AUR101-201</org_study_id>
    <nct_id>NCT04207801</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Evaluate Efficacy &amp; Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis</brief_title>
  <acronym>INDUS-2</acronym>
  <official_title>A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized, Study to Evaluate the Efficacy and Safety of Two Doses of AUR101 in Patients With Moderate-to-Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurigene Discovery Technologies Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurigene Discovery Technologies Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study
      to evaluate efficacy and safety of AUR101 (RORgamma inhibitor) in patients with
      moderate-to-severe psoriasis.

      Approximately 90 patients with chronic moderate-to-severe plaque psoriasis will be randomized
      to the 2 dose groups of AUR101 and one group of Placebo. The patients will receive the
      treatment for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study
      to evaluate efficacy and safety of two doses of AUR101 in patients with moderate-to-severe
      psoriasis.

      Approximately 90 patients with chronic moderate-to-severe plaque psoriasis (defined as
      Psoriasis Area and Severity Index (PASI) ≥12 and Body Surface Area (BSA) involved ≥10%) will
      be randomized to the 2 dose groups of AUR101 and placebo in the ratio of 1:1:1.

      The patients in each arm will receive AUR101 of 400 mg twice daily or AUR101 600 mg twice
      daily or matching placebo twice daily for 12 weeks in a double blind, double dummy fashion.

      Every patient will receive 12 weeks of treatment. All the patients will be followed up for 14
      ± 2 days of their last dose for safety assessment.

      A subset of approximately 25 patients, who consent, will be asked to come for plasma PK
      assessment in week 4 of dosing.

      Efficacy evaluation will be done by PASI, DLQI and BSA assessment. Safety assessment will be
      done by AEs and regular lab assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 (i.e. 75% reduction from baseline PASI score). (Scores range from 0 (minimum) to 30 (maximum))</measure>
    <time_frame>week 12</time_frame>
    <description>Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 (i.e. 75% reduction from baseline PASI score). (Scores range from 0 (minimum) to 30 (maximum))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 (i.e. 75% reduction from baseline PASI score). (Scores range from 0 (minimum) to 30 (maximum))</measure>
    <time_frame>week 4 and 8.</time_frame>
    <description>Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 (i.e. 75% reduction from baseline PASI score). (Scores range from 0 (minimum) to 30 (maximum))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 50 (i.e. 50% reduction from baseline PASI score). (Scores range from 0 (minimum) to 30 (maximum))</measure>
    <time_frame>week 4,8 and 12</time_frame>
    <description>Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 50 (i.e. 50% reduction from baseline PASI score). (Scores range from 0 (minimum) to 30 (maximum))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Investigator Global Assessment (IGA) (Scores range from 0 (0 or 1 clear to mild) to 4 (severe))</measure>
    <time_frame>week 4,8 and 12</time_frame>
    <description>Proportion of patients achieving Investigator Global Assessment (IGA) (Scores range from 0 (0 or 1 clear to mild) to 4 (severe))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Psoriasis Area and Severity Index (PASI) score. (Scores range from 0 (minimum) to 30 (maximum))</measure>
    <time_frame>week 4,8 and 12</time_frame>
    <description>Percent change from baseline in Psoriasis Area and Severity Index (PASI) score. (Scores range from 0 (minimum) to 30 (maximum))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Investigator Global Assessment (IGA) scale (Scores range from 0 (0 or 1 clear to mild) to 4 (severe))</measure>
    <time_frame>week 4,8 and 12</time_frame>
    <description>Change from baseline in Investigator Global Assessment (IGA) scale (Scores range from 0 (0 or 1 clear to mild) to 4 (severe))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 4, 8 and 12 in percent Body Surface Area (BSA) involved</measure>
    <time_frame>week 4,8 and 12</time_frame>
    <description>Change from baseline to week 4, 8 and 12 in percent Body Surface Area (BSA) involved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 4, 8 and 12 in Dermatology Life Quality Index (DLQI) (Scores range from 0 to 30, and higher scores indicate greater health-related quality-of life impairment.)</measure>
    <time_frame>week 4,8 and 12</time_frame>
    <description>Change from baseline to week 4, 8 and 12 in Dermatology Life Quality Index (DLQI) (Scores range from 0 to 30, and higher scores indicate greater health-related quality-of life impairment.)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Chronic Plaque-type Psoriasis</condition>
  <arm_group>
    <arm_group_label>Arm-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg AUR101 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg AUR101 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm-3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUR101</intervention_name>
    <description>Inhibitor of RORγ</description>
    <arm_group_label>Arm-1</arm_group_label>
    <arm_group_label>Arm-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Drug-Placebo of AUR101 tablet</description>
    <arm_group_label>Arm-3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Confirmed diagnosis of chronic plaque-type psoriasis, diagnosed at least 6 months
             before screening

             2. Psoriasis of at least moderate severity, defined as PASI≥12 and involved BSA≥10 %
             at screening and Day 1

             3. Adult males or females,≥18 to ≤ 65 years of age.

             4. Ability to communicate well with the investigator and to comply with the
             requirements of the entire study

             5. Willingness to give written informed consent (prior to any study related procedures
             being performed) and ability to adhere to the study restrictions and assessments
             schedule.

        Exclusion Criteria:

          -  1. History of erythrodermic, guttate, or pustular psoriasis within last 12 months

             2. Efficacy failure on any biologic (e.g. interleukin (IL) -17 antibodies or anti-TNF
             agents) for the treatment of psoriasis.

             3. Static 5-point IGA mod 2011 scale of 0 to 2 at screening or Day 1.

             4. BMI ≥ 35 kg/m2

             5. Current treatment or history of treatment for psoriasis with IL-17 or IL-12/23
             antagonist biological agents within 6 months prior to study day 1

             6. Current treatment or history of treatment for psoriasis with other biological
             agents within 3 months prior to study day 1.

             7. Current treatment or history of treatment for psoriasis with non-biological
             systemic medications or phototherapy within 4 weeks prior to study day 1.

             8. Treatment with medicated topical agents within 2 weeks prior to study day 1.

             9. History or presence of any medical or psychiatric disease, or clinically
             significant laboratory at screening,

             10. Evidence of organ dysfunction

             11. Any major recent surgery history within 3 months prior to screening

             12. Alcohol abuse or drug abuse

             13. History of malignancy

             14. Positive for HIV, Hepatitis B or Hepatitis C at screening.

             15. Patient with known past history of systemic tuberculosis or currently suspected or
             known to have tuberculosis

             16. Patient expected to be started on anti-tubercular therapy either for treatment or
             prophylaxis of tuberculosis.

             17. Suspected tuberculosis infection as evident from a positive QuantiFERON TBGold
             test (QFT) at screening. Patients with a positive QFT test may participate in the
             study if further work up as per the opinion of the investigator .

             18. History of hypersensitivity or idiosyncratic reaction to any investigational
             RORgamma inhibitors or any of the excipients of study drug

             19. Past gastrointestinal surgery or recent (within 3 months) / current history of
             gastrointestinal disease.

             20. Positive pregnancy test for women of child bearing potential (WOCBP) at the
             screening or randomization visit

             21. Male patients with partners of childbearing potential not willing to use reliable
             contraception methods.

             22. Pregnant or lactating women or WOCBP who are neither surgically sterilized nor
             willing to use reliable contraceptive methods

             23. Has received another new chemical entity/investigational drug within 28 days or 5
             half-lives of investigational drug prior to study day 1.

             24. Use of herbal remedies, mega dose vitamins and minerals during the 2 weeks prior
             to the first administration of investigational product.

             25. Patients who have received live or attenuated vaccine in the 4 weeks prior to
             study day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shilendra Pandey, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Aurigene Discovery Techologies Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Divyesh Mandavia, MD</last_name>
    <phone>+918071025588</phone>
    <email>divyesh_m@aurigene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shilendra Pandey, MSc</last_name>
    <phone>+919873554523</phone>
    <email>shilendra_p@aurigene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Govt. General Hospital &amp; Medical College</name>
      <address>
        <city>Srikakulam</city>
        <state>Andhra Pradesh</state>
        <zip>532001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kanaka Prasad Rao M, MD</last_name>
      <phone>+919948741133</phone>
      <email>rimsresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kanaka Prasad Rao M, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>B.J Medical College &amp; Civil Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Bela Shah, MD</last_name>
      <phone>+919898059289</phone>
      <email>shah.drbela@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Bela Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kempegowda Institute of Medical Sciences</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Nandini A S, MD</last_name>
      <phone>+919886829579</phone>
      <email>drnandinias2002@yahoo.co.in</email>
    </contact>
    <investigator>
      <last_name>Dr. Nandini A S, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sapthagiri Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560090</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Savitha A S, MD</last_name>
      <phone>+919880512166</phone>
      <email>drsavithasomaiah@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Savitha A S, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grant Medical college and JJ Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Mahendra Kura, MD</last_name>
      <phone>+919322593511</phone>
      <email>drkura@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Mahendra Kura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shree Hospital and Critical Care Centre</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440009</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Shyamal Balki, MD</last_name>
      <phone>+919665477444</phone>
      <email>drshyamalb@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Shyamal Balki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440019</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Sushil Pande, MD</last_name>
      <phone>+919323511245</phone>
      <email>drsushilpande@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Sushil Pande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sujata Birla Hospital &amp; Medical Research Center</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422101</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Suneel Vartak, MD</last_name>
      <phone>+919373901829</phone>
      <email>suneel.vartak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Suneel Vartak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calcutta National Medical College</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700014</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Abhisekh De, MD</last_name>
      <phone>+919903275551</phone>
      <email>dr_abhishek_de@yahoo.co.in</email>
    </contact>
    <investigator>
      <last_name>Dr Abhisekh De, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College and Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700073</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Abanti saha, MD</last_name>
      <phone>+919432146692</phone>
      <email>sahaaby@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Abanti saha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education &amp; Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160 012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Sunil Dogra, MD</last_name>
      <phone>+919855005941</phone>
      <email>sundogra@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Sunil Dogra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AUR101</keyword>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not yet planned to share</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

